Gilead Sciences

News

Gilead Q3 revenue rise bolstered by $873m Veklury sales

Gilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment with its Veklury antiviral, and its latest financial results reveal the benefit of that a

News

BioSig abandons COVID-19 drug trial on safety concerns

US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury in severe COVID-19 patients, after concluding the safety of the combinat

News

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

News

EU ramps up supply of COVID-19 vaccine, drugs

The European Commission has taken its advance orders for potential COVID-19 vaccines to more than 1.1 billion, after signing a supply deal for up to 400 million doses of Johnson & Johns

News

Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-...

Adding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients compared to remdesivir alone, says a new trial

News

There are three types of white blood cells. T lymphocytes, B lymphocytes and natural killer cells.

Gilead’s Kite gains some height after second CAR-T approval ...

Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T

Gilead Q3 revenue rise bolstered by $873m Veklury sales

BioSig abandons COVID-19 drug trial on safety concerns

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

EU ramps up supply of COVID-19 vaccine, drugs

Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-...

Gilead’s Kite gains some height after second CAR-T approval ...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Gilead Sciences

Editor's Picks